logo
Johns Hopkins Hospital celebrates remarkable recoveries, life-saving medical professionals

Johns Hopkins Hospital celebrates remarkable recoveries, life-saving medical professionals

CBS News21-05-2025
Johns Hopkins Hospital is celebrating thousands of inspiring recovery journeys, and the medical care teams who helped save their lives.
To mark the occasion, the hospital held a special event on Wednesday in honor if National Trauma Survivors Day.
Survivors shared their personal stories of recovery and reunited with the care teams who played a vital role in their care.
"They say it takes a village, and you all proved it"
Mark McKenzie did not know if he would survive being shot in 2024.
"As you can see, I'm blessed to have many of the most important people in my life here today, and I'm quite certain they all only came because they thought it was a roast," said Mark McKenzie, a trauma survivor.
The joy on this stage means much more because on September 13, 2024, McKenzie was rushed to the hospital after being shot in the chest and abdomen.
Johns Hopkins Hospital
"Medic one arrived in less than four minutes, which is a very quick response," said Angela Taury, an EMS captain with the Baltimore County Fire Department. "So not only did we have to respond to a critical injury, but it was also an active crime scene, so we had to work quickly but carefully with the police. You know, they're guiding us."
Doctors say McKenzie required immediate surgery and later underwent liver repair, gallbladder removal, and vein reconstruction.
"I also firmly believe in the power of prayer, and I believe that God intervened on that Friday the 13th," McKenzie said.
"We had to put a plan together, we had to go to work, and the surgery was difficult, and the recovery was long. I'm thrilled to be here today. Mark's at home with his family, thriving, and it's an incredible victory for us and for you," said Dr. Chris Shubert, a hepatobiliary and pancreatic surgeon at Johns Hopkins Hospital.
The road to recovery
McKenzie spent 47 days in the hospital, with 38 of those days in the intensive care unit.
On Wednesday, he was in a room filled with the nurses, doctors, family, and a long list of friends, saying, "I survived."
"They say it takes a village, and you all proved it," McKenzie said. "They gave me back, they gave me back life to be with my wife and my kids."
Reunited with the survivors
From the emergency crews who responded to the initial 911 call to the medical care team who stood by his bedside, everyone had a chance to reunite with the patient who never gave up.
Johns Hopkins Hospital
"But rarely do we get to follow up or see what happens afterward. So to be here with you today is truly meaningful," said Taury.
"Mark has climbed through every step or setback of his medical journey with tenacity and a sense of humor," said Amy Lowe, a physical therapist at Johns Hopkins Rehabilitation Network Center in Timonium.
"You faced a traumatic event that really would have brought most of us to her knees," Jennifer Zanni, a long-time physical therapist at Johns Hopkins Rehabilitation Network Center. "And [you] really have shown that through healing, is really not about forgetting the trauma, but learning to carry it in a way that allows you your life to move forward."
More survivors honored
The event also recognized the team and survival stories of 14-year-old Ethan McKinnon and 24-year-old John Paredes.
McKinnon sustained severe injuries when the car he was in with his family was rear-ended at high speed. Ejected from the vehicle, Ethan suffered aortic, spinal, and small bowel injuries. He required spinal fusion surgeries, had a breathing tube for several days and needed feeding support.
Paredes was admitted in March 2024, with elevated eye pressure and blurry vision as a result of an elastic band hitting his eye during boxing training. He was diagnosed with indeterminate stage angle recession glaucoma and vitreous prolapse of the right eye, requiring several eye surgeries.
Together, all of the trauma and burn centers at Hopkins have treated more than 5,093 patients since 2024, including the three they honored on National Trauma Survivors Day.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today

Yahoo

time8 minutes ago

  • Yahoo

If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today

Key Points Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly awaiting trial results later this year. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy. One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Viking Therapeutics: The best may be yet to come The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success. Where is this promising drug now VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year. Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss. The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing. These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool

Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting
Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting

Yahoo

time8 minutes ago

  • Yahoo

Bausch Health (BHC) Rebounds 15.8% on Bargain-Hunting

We recently published . Bausch Health Companies Inc. (NYSE:BHC) is one of the best-performing stocks on Monday. Bausch Health bounced back by 15.83 percent on Monday to close at $6.66 apiece as investors appeared to have hunted for bargains, having traded below the $6 level for seven days in a row. Monday's share price marked Bausch Health Companies Inc. (NYSE:BHC) first official claw back to the green territory since the start of the month after hovering for most of the trading days below the $5.89 closing price on July 31. It picked up to $5.94 on August 5, but only by a slight 0.85-percent gain from July 31's closing price. Year-to-date, the company's shares were down by 17.4 percent. In recent news, Bausch Health Companies Inc. (NYSE:BHC) expanded its attributable net income by 1,380 percent in the second quarter of the year to $148 million from only $10 million in the same period last year. Revenues also grew by 5 percent to $2.53 billion from $2.4 billion. Copyright: nimon / 123RF Stock Photo For the full-year period, Bausch Health Companies Inc. (NYSE:BHC) raised its revenue guidance to $10 billion to $10.25 billion, as compared with the $9.95 billion to $10.2 billion previously. While we acknowledge the potential of BHC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Fertility Startup Gameto Raises $44 Million to Test Egg-Freezing Therapy in US
Fertility Startup Gameto Raises $44 Million to Test Egg-Freezing Therapy in US

Bloomberg

time10 minutes ago

  • Bloomberg

Fertility Startup Gameto Raises $44 Million to Test Egg-Freezing Therapy in US

Gameto Inc., a biotech company working on stem-cell therapies for women's health, has raised $44 million in venture capital to help fund a clinical trial for its product that aims to improve the egg-freezing experience. The funding round, led by Overwater Ventures, will let Gameto bring its Fertilo therapy closer to US Food and Drug Administration approval. The technique, which uses stem cells that have been engineered into ovarian support cells, is intended to free patients from the grueling two weeks of injections that prompt ovaries to make enough eggs during fertility treatment. In a Phase 3 trial, patients are only given three days of injections, after which their eggs are extracted and matured by the engineered cells.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store